PR Newswire
Novartis shareholders awoke to a more than 12.5% decline at open on September 8, 2026, after the Company reported that its Phase 3 HARBOR study of del-desiran and Phase 3 HORIZON study of pelacarsen did not meet their respective primary endpoints. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of NVS investors.
NEW YORK, Sept. 9, 2026 /PRNewswire/ — Novartis AG (NYSE:NVS) opened down more than $20 per share, or more than 12.5%, following the Company’s disclosures that its Phase 3 HARBOR and HORIZON studies had both failed to meet their primary endpoints. If you held NVS shares through that session and lost money, you are encouraged to have your NVS losses reviewed at no cost. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.
Following the close of market on Friday, September 4, 2026, Novartis announced pelacarsen had failed to meet its primary endpoint in the Phase 3 HORIZON trial. The drug trial was reprotedly unsuccessful in demonstrating a benefit of pelacarsen over placebo in reducing the risk of cardiovascular events compared to placebo.
Then, before the market opened on Tuesday, September 8, 2026, Novartis announced that its experimental drug, del-desiran, also failed to meet its primary endpoint in the Phase 3 HARBOR trial for myotonic dystrophy type 1. The drug fell short of demonstrating a significant benefit over placebo in the video hand opening time (vHOT) measurement. Del-desiran came to Novartis through its approximately $12 billion acquisition of Avidity Biosciences.
NVS shareholders who lost money on September 8 may submit their loss information for review or call (888) SueWallSt to speak with an attorney about their options.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the NVS Investigation
Q: How much did NVS stock drop?A: Shares opened down more than 12.5% on September 8, 2026, after the Company reported that the Phase 3 HARBOR and Phase 3 HORIZON studies both failed to meet their primary endpoints. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: Who is eligible to participate in the NVS investigation?A: Investors who purchased NVS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Novartis made materially false or misleading statements regarding the subject drug programs and corresponding studies. When the Company reported that the studies did not meet their primary endpoints, the stock price declined sharply.
Q: What do NVS investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What is a lead plaintiff and why does it matter?A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.
Q: What if I already sold my NVS shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NVS and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.
Q: What if I live outside the United States?A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/novartis-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-novartis-nvs-302874095.html
SOURCE SueWallSt.com
